BRPI0411321A - vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus - Google Patents

vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus

Info

Publication number
BRPI0411321A
BRPI0411321A BRPI0411321-7A BRPI0411321A BRPI0411321A BR PI0411321 A BRPI0411321 A BR PI0411321A BR PI0411321 A BRPI0411321 A BR PI0411321A BR PI0411321 A BRPI0411321 A BR PI0411321A
Authority
BR
Brazil
Prior art keywords
adenovirus
viral vector
associated viral
pharmaceutical composition
treating alzheimer
Prior art date
Application number
BRPI0411321-7A
Other languages
English (en)
Inventor
Takeshi Tabira
Hideo Harai
Original Assignee
Japan Government
Nat Inst Of Biomedical Innovat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Government, Nat Inst Of Biomedical Innovat filed Critical Japan Government
Publication of BRPI0411321A publication Critical patent/BRPI0411321A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"VETOR VIRAL ASSOCIADO A ADENOVìRUS, COMPOSIçãO FARMACêUTICA E MéTODO PARA TRATAR DOENçA DE ALZHEIMER, E, USO DO VETOR VIRAL ASSOCIADO A ADENOVìRUS". Um vetor viral associado a adenovírus capaz de expressar um fragmento de peptídeo contendo uma região de indução de imunidade líquida do peptídeo <225>-amilóide, que compreende uma codificação de DNA para o fragmento de peptídeo na forma funcional.
BRPI0411321-7A 2003-06-13 2004-06-11 vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus BRPI0411321A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003169714 2003-06-13
JP2003371103A JP4888876B2 (ja) 2003-06-13 2003-10-30 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
PCT/JP2004/008224 WO2004111250A1 (ja) 2003-06-13 2004-06-11 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター

Publications (1)

Publication Number Publication Date
BRPI0411321A true BRPI0411321A (pt) 2006-07-18

Family

ID=33554414

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411321-7A BRPI0411321A (pt) 2003-06-13 2004-06-11 vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus

Country Status (15)

Country Link
US (1) US8318687B2 (pt)
EP (1) EP1634956B1 (pt)
JP (1) JP4888876B2 (pt)
KR (1) KR20060029225A (pt)
AT (1) ATE466093T1 (pt)
AU (1) AU2004248014B2 (pt)
BR (1) BRPI0411321A (pt)
CA (1) CA2529179C (pt)
DE (1) DE602004026867D1 (pt)
DK (1) DK1634956T3 (pt)
ES (1) ES2345151T3 (pt)
NZ (1) NZ544554A (pt)
PT (1) PT1634956E (pt)
RU (1) RU2335542C2 (pt)
WO (1) WO2004111250A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR100677051B1 (ko) 2005-03-18 2007-02-01 주식회사 엘지화학 올레핀으로부터 불포화산을 제조하는 방법
EP1891215B1 (en) * 2005-04-20 2009-10-28 Dnavec Corporation Highly safe intranasally administrable gene vaccines for treating alzheimer's disease
JP4903159B2 (ja) * 2005-04-20 2012-03-28 ディナベック株式会社 アルツハイマー病の治療のための安全性に優れた鼻腔内投与可能遺伝子ワクチン
WO2006126682A1 (ja) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute アルツハイマー病の予防・治療用ワクチン
CN105039313B (zh) 2005-06-23 2018-10-23 科因股份有限公司 用于多态性的高通量鉴定和检测的策略
CA2910861C (en) 2005-09-29 2018-08-07 Michael Josephus Theresia Van Eijk High throughput screening of mutagenized populations
US10316364B2 (en) 2005-09-29 2019-06-11 Keygene N.V. Method for identifying the source of an amplicon
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
JP5452021B2 (ja) 2005-12-22 2014-03-26 キージーン ナムローゼ フェンノートシャップ ハイスループットａｆｌｐ系多型検出法
US20090253581A1 (en) 2006-04-04 2009-10-08 Keygene N.V. High Throughput Detection of Molecular Markers Based on AFLP and High Throughput Sequencing
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2011052679A1 (ja) 2009-11-02 2011-05-05 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
JP5697044B2 (ja) * 2010-01-08 2015-04-08 国立大学法人京都大学 タウオパチー治療用ワクチン
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
JP6342886B2 (ja) 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
AU2018206304A1 (en) 2017-01-06 2019-07-04 Stabilitech Biopharma Ltd Virus
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
KR102922353B1 (ko) * 2020-12-18 2026-02-04 베일러 칼리지 오브 메디신 응집 억제를 위한 Aβ 변이체의 전달
US20250049955A1 (en) 2021-11-17 2025-02-13 Voyager Therapeutics, Inc. Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
AU2486900A (en) 1998-12-29 2000-07-31 University Of Georgia Research Foundation, Inc., The Rubredoxin fusion proteins, protein expression system and methods
WO2001006989A2 (en) * 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
EP1363939A2 (en) * 2000-11-01 2003-11-26 Insight Biotechnology Limited Peptides for use in the treatment of alzheimer's disease
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
CN100450551C (zh) * 2002-11-29 2009-01-14 中国医学科学院基础医学研究所 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途

Also Published As

Publication number Publication date
JP4888876B2 (ja) 2012-02-29
JP2005021149A (ja) 2005-01-27
RU2335542C2 (ru) 2008-10-10
EP1634956B1 (en) 2010-04-28
AU2004248014A1 (en) 2004-12-23
AU2004248014B2 (en) 2008-12-04
ES2345151T3 (es) 2010-09-16
US20090004144A1 (en) 2009-01-01
CA2529179A1 (en) 2004-12-23
US8318687B2 (en) 2012-11-27
WO2004111250A1 (ja) 2004-12-23
KR20060029225A (ko) 2006-04-05
RU2006101149A (ru) 2006-06-27
DE602004026867D1 (de) 2010-06-10
CA2529179C (en) 2012-08-21
PT1634956E (pt) 2010-06-23
EP1634956A1 (en) 2006-03-15
EP1634956A4 (en) 2007-01-24
NZ544554A (en) 2010-06-25
DK1634956T3 (da) 2010-08-16
ATE466093T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
BRPI0109131B8 (pt) dna, vetor de expressão compreendendo o mesmo, fator viii modificado de porcino, seu processo de produção e composição terapêutica compreendendo o mesmo
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
DE60032486D1 (de) Prion protein peptide und deren verwendung
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
ECSP045191A (es) &#34;nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c&#34;
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
MXPA02010787A (es) Peptidos modificados como agentes terapeuticos.
EP1495128A4 (en) IMPROVED PROTEIN EXPRESSION IN BACILLUS
NO992102D0 (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
BR0209254A (pt) anticorpos de bloqueio cripto e usos dos mesmos
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ECSP024352A (es) Nueva composicion farmaceutica
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
DK1634956T3 (da) Rekombinant andeno-associeret virusvektor til behandling af Alzheimers sygdom
UY28348A1 (es) Compuestos novedosos
CO6341637A2 (es) \\\\\\\&#34;composiciones y metodos novedosos\\\\\\\&#34;
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
BR0007035A (pt) Métodos de controle de pragas de agrótis

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION (JP) ,

Free format text: NOME ALTERADO DE: JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY

B25G Requested change of headquarter approved

Owner name: NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION (JP) ,

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110021588/RJ DE 03/03/2011.

B25A Requested transfer of rights approved

Owner name: NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP

Free format text: TRANSFERIDO DE: NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.